Marine Natural Products: A Source of Novel Anticancer Drugs
Authors:
- Shaden A. M. KhalifaSKShaden A. M. Khalifa
- Nizar EliasNizar Elias
- Lei ChenLCLei Chen
- Aamer SaeedASAamer Saeed
- Mohamed-Elamir F. HegazyMohamed-Elamir F. Hegazy
- Moustafa S. MoustafaMMMoustafa S. Moustafa
- Aida Abd El-WahedAEAida Abd El-Wahed
- Saleh M. Al-MousawiSASaleh M. Al-Mousawi
- Syed G. MusharrafSMSyed G. Musharraf
- Fang-Rong ChangFang-Rong Chang
- Arihiro IwasakiAIArihiro Iwasaki
Top Cited Papers
Open Access
- 23 August 2019
- journal article
- research article
- Published by MDPI AG in Marine Drugs
- Vol. 17 (9) , 491
Abstract
Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.Keywords
Funding Information
- Uppsala Universitet (Swedish Research links grant 2016-05885 (VR for the years 2017 - 2019))
This publication has 201 references indexed in Scilit:
- Marine-Derived Angiogenesis Inhibitors for Cancer TherapyMarine Drugs, 2013
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Structure and Absolute Configuration of Karlotoxin-2, an Ichthyotoxin from the Marine Dinoflagellate Karlodinium veneficumJournal of the American Chemical Society, 2010
- Mechanistic Studies of Sansalvamide A-Amide: An Allosteric Modulator of Hsp90ACS Medicinal Chemistry Letters, 2010
- Discovery and development of the anticancer agent salinosporamide A (NPI-0052)Bioorganic & Medicinal Chemistry, 2009
- Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium Leptolyngbya sp.Journal of the American Chemical Society, 2008
- Lophocladines, Bioactive Alkaloids from the Red Alga Lophocladia sp.Journal of Natural Products, 2006
- Natural Products as Sources of New Drugs over the Period 1981−2002Journal of Natural Products, 2003
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie International Edition, 2003
- Cyclic peptides and depsipeptides from cyanobacteria: A reviewJournal of Industrial Microbiology and Biotechnology, 1996